PMV Pharmaceuticals(US:PMVP)2025-05-09 12:00Financial Performance - PMV Pharmaceuticals ended Q1 2025 with $165.8 million in cash, cash equivalents, and marketable securities, down from $183.3 million as of December 31, 2024[5]. - Net loss for Q1 2025 was $17.5 million, compared to a net loss of $15.3 million for Q1 2024, representing an increase of approximately 14.3%[7]. - PMV Pharma's total assets decreased to $170.6 million as of March 31, 2025, from $191.3 million as of December 31, 2024[13]. - The company reported a net loss per share of $0.34 for Q1 2025, compared to $0.30 for Q1 2024[14]. Expenses - Research and development (R&D) expenses increased to $17.4 million in Q1 2025 from $13.2 million in Q1 2024, reflecting a rise of approximately 32.4%[7]. - General and administrative (G&A) expenses decreased to $4.1 million in Q1 2025 from $5.0 million in Q1 2024, a reduction of approximately 18%[7]. - Total operating expenses for Q1 2025 were $21.6 million, compared to $18.2 million in Q1 2024, marking an increase of approximately 18.5%[14]. Future Plans and Developments - The company plans to provide interim analysis data from the Phase 2 PYNNACLE trial in mid-2025, involving approximately 50 patients, with around 40% in the ovarian cancer cohort[3]. - PMV Pharma's cash runway is expected to extend to the end of 2026 based on current cash reserves[6]. - The FDA granted Fast Track designation to rezatapopt for treating patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation[8].